Zelira Therapeutics (ASX:ZLD) Volatility: 68.98% (As of Jun. 26, 2026)


What is Zelira Therapeutics Volatility?

Zelira Therapeutics ASX:ZLD Volatility is 68.98% as of Jun. 26, 2026. The stock has 7 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-26), Zelira Therapeutics's Volatility is 68.98%.

Zelira Therapeutics  (ASX:ZLD) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Zelira Therapeutics Volatility Related Terms

ASX:ZLD vs ENSC, PPCB, ACUT: Volatility Comparison

For the Biotechnology subindustry, Zelira Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zelira Therapeutics Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where Zelira Therapeutics's Volatility falls into.


Zelira Therapeutics  (ASX:ZLD) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 68.98% mean?
Zelira Therapeutics (ASX:ZLD) has a Volatility of 68.98% as of Jun. 26, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' Volatility too high?
Zelira Therapeutics' current Volatility is 68.98%.
How does Zelira Therapeutics' Volatility compare to ENSC and PPCB?
Zelira Therapeutics' Volatility of 68.98% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current Volatility is 68.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ASX:ZLD) has a current Volatility of 68.98%. The stock's GF Value™ is A$0.12, compared to a current price of A$0.50 — trading 316.7% above its estimated fair value. The current Volatility is 68.98%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Zelira Therapeutics (ASX:ZLD), the current Volatility is 68.98% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelira Therapeutics Business Description

Other Exchanges ZLDAF:USA
Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.